Contract Manufacturing in Pharmaceutical industry: Regulatory, Business & Market Perspectives

The model of Contract Development and Manufacturing Organization (CDMO)

03 December 2025
2 min read
Contract Manufacturing in Pharmaceutical industry: Regulatory, Business & Market Perspectives

Introduction

The model of Contract Development and Manufacturing Organization (CDMO) — also referred to as toll manufacturing or contract manufacturing — has become a cornerstone for flexibility and innovation in the global pharmaceutical industry. Through this approach, licence holder with third-party manufacturers for drug development, production, and packaging without building their own facilities.

Regulatory Compliance

  • In Indonesia, contract manufacturing of pharmaceuticals is permitted only for companies holding valid Good Manufacturing Practice (GMP / CPOB) certification
  • The regulatory framework enforced by the national drug authority, Badan Pengawas Obat dan Makanan (BPOM), requires that any outsourced manufacturing adheres strictly to GMP standards — covering quality control, sanitation, documentation, and facility qualification
  • A formal, written manufacturing agreement (technical agreement) is essential, delineating responsibilities including formula ownership, batch records, change control, quality assurance, regulatory compliance, margin of liability, and supply chain management
  • Even when production is outsourced, the MAH remains legally accountable for final product safety, efficacy, and quality

Strategy & Advantages toll manufacturing

Adopting a CDMO / toll manufacturing model offers multiple strategic benefits for pharmaceutical companies:

  • CapEx savings: Avoids the large capital investment required to build and maintain manufacturing facilities.
  • Focus on core competencies: Enables firms to concentrate on branding, marketing, regulatory affairs, and distribution while leaving production to specialists.
  • Scalability and flexibility: Ideal for rapid product launch, scaling up manufacturing or entering new markets without delay.
  • Access to specialized expertise and technology: For complex formulations, advanced dosage forms, high-volume production, or regulatory-grade manufacturing for export markets.

Challenges do exist — ensuring batch-to-batch consistency, managing supply chain dependencies, logistics, and maintaining control over quality standards.